NEW YORK, March 16, 2015 /PRNewswire/ -- S&P
Capital IQ (MHFI) announced today that it has commenced Factual
Stock Report coverage on ANGLE Plc.
ANGLE Plc (OTCQX: ANPCY; LSE AIM: AGL) is a specialist medical
diagnostic company with products in cancer diagnostics and fetal
health. The company has substantially completed its transition to a
specialist medical diagnostics company from a broader venture
business building and services based company and GICS codes will be
revised in due course. The company's lead product is the
patent-protected Parsortix cell separation device, which can
capture very rare circulating tumor cells (CTCs) in cancer patient
blood, even when there is less than one CTC in one billion healthy
cells. The resulting liquid biopsy (simple blood test) enables the
investigation of mutations in the patient's cancer for personalized
cancer care. ANGLE has launched a product for the research market
and has secured CE Mark regulatory approval for the clinical market
in Europe. FDA approval is
targeted for 2015.
The Parsortix GEN3 Cassette works with a variety of cancers
including prostate, breast, ovarian, pancreatic, colorectal, lung
and renal. It does not require the use of antibodies and is capable
of harvesting circulating tumor cells for molecular analysis.
The Parsortix system has a number of key features. Unlike other
systems, the Parsortix system does not rely on the CTCs expressing
specific cell surface markers for isolation for antibody binding.
This means that all the cancer cells can be captured. In addition,
the Parsortix system is applicable for all solid cancers including
those with weak or no cell surface markers. The Parsortix system
can be used without modification with a wide range of cancers. The
company also notes that cells which are captured by the Parsortix
system have not been subjected to antibody binding or other
chemical reaction as part of the capture process. This offers the
potential to capture intact undamaged cells for detailed
analysis.
The Parsortix system is biomarker compatible. CTCs captured by
the Parsortix system can be harvested for detailed molecular
analysis. This liquid biopsy from a simple blood test enables the
potential for personalized cancer treatment with patients receiving
drugs which directly target their own cancer.
ANGLE says the Parsortix system is easy to use and can be used
with whole blood samples, direct from a simple blood test, without
any pre-processing of the blood such as red blood cell removal.
This makes the process easy and cost effective, the company notes,
while ensuring that unnecessary loss of target cells is minimized.
ANGLE also notes that the Parsortix system can handle blood volumes
of less than 1ml and up to 50ml enabling a wide range of
applications.
During FY 14 (April), a specialist, large-scale manufacturer was
appointed to manufacture the Parsortix system with the necessary
quality systems and capacity to support the roll out into the
research and clinical markets.
ANGLE believes that it made significant progress with
commercialization of Parsortix during FY 14, and it is now strongly
focused on establishing the use of the system in clinical practice.
To achieve this, the top priority is the establishment of
collaborations with key opinion leaders at world class research
centers. The company says that these key opinion leaders are
working to identify applications with medical utility (clear
benefit to patients), and to secure clinical data that demonstrates
that utility in patient studies.
The company noted that Cancer Research UK Manchester Institute
completed a full report confirming key competitive advantages of
the Parsortix system. These include applicability to multiple types
of cancer cells including mesenchymal cells, applicability to
multiple types of cancer, easy harvesting of cells for molecular
analysis, and a low level of background white blood cell
contamination of harvested cell samples.
In addition, ANGLE has an agreement with the Medical Research
Council's Cancer Unit at the University of
Cambridge to establish a Cambridge Parsortix Laboratory. The
agreement will allow research teams to have improved access to the
Parsortix system.
The Parsortix system has also been used by the University of
Surrey Oncology Group in a metastatic liver cancer patient
study.
On January 23, 2015, the Company
announced a collaboration agreement with EKF Diagnostics Holdings
plc to investigate the combination of the Parsortix system with
EKF's PointMan™DNA enrichment technology as a liquid biopsy.
On January 27, 2015, the company
announced that following highly convincing patient data, the
Medical University of Vienna
reported that the Parsortix system delivers "unprecedented
sensitivity and specificity" and will now lead, in collaboration
with ANGLE, a clinical study of the use of the Parsortix system as
a clinical application in the routine detection and treatment of
ovarian cancer patients.
ANGLE's major focus is on the cancer market. However, it
believes that there is also a substantial market available in
non-invasive fetal diagnostics, harvesting fetal cells from the
pregnant mother and analyzing for Down's Syndrome and many other
chromosomal and genetic conditions through a simple blood test.
ANGLE Plc is based in Guildford, Surrey,
United Kingdom and University City Science Centre,
Philadelphia.
S&P Capital IQ's Factual Stock Report coverage on ANGLE Plc
will also be accessible on an ongoing basis to the investment
community by scores of buy-side institutions and sell-side firms
that utilize S&P Capital IQ research and information platforms
daily. Millions of self-directed investors also have access to the
report via their e-brokerage accounts. Please visit
http://www.angleplc.com for additional information.
About S&P Capital IQ's Factual Stock Reports
Currently profiling approximately 400 issuers, S&P Capital
IQ (MHFI) Factual Stock Reports increase market awareness of
issuers in the investment community with insightful commentary, key
statistics, and relevant corporate information. The Reports
provide factual research coverage about company fundamentals and
business prospects, thereby enabling information on the covered
companies to reach a wide spectrum of Buy and Sell-side investors.
Updated weekly with the latest pricing, trading volume, and other
data, the Reports also capture recent company developments, a
financial review, key operating information, industry and peer
comparisons, Street Consensus, performance charts, business
summary, fundamental data, and timely news stories. Coverage of
these reports is underwritten by the issuer, therefore S&P
Capital IQ does not offer investment opinions concerning the
advisability of investing in these stocks.
S&P Capital IQ Factual Stock Reports are produced separately
from any other analytic activity of S&P Capital IQ or related
organizations. S&P Capital IQ does not trade on its own
account.
About S&P Capital IQ
S&P Capital IQ, a part of McGraw Hill Financial (NYSE:
MHFI), is a leading provider of multi-asset class and real time
data, research and analytics to institutional investors, investment
and commercial banks, investment advisors and wealth managers,
corporations and universities around the world. S&P Capital IQ
provides a broad suite of capabilities designed to help track
performance, generate alpha, and identify new trading and
investment ideas, and perform risk analysis and mitigation
strategies. Through leading desktop solutions such as the S&P
Capital IQ, Global Credit Portal and MarketScope Advisor desktops;
enterprise solutions such as S&P Capital IQ Valuations; and
research offerings, including Leveraged Commentary & Data,
Global Markets Intelligence, and company and funds research,
S&P Capital IQ sharpens financial intelligence into the wisdom
today's investors need. For more information, visit
www.spcapitaliq.com.
In the United States, research
reports are prepared by Standard & Poor's Investment Advisory
Services LLC, a part of S&P Capital IQ and a registered
investment adviser with the U.S. Securities and Exchange
Commission. S&P Capital IQ provides a broad suite of
capabilities designed to help track performance, generate alpha,
and identify new trading and investment ideas, and perform risk
analysis and mitigation strategies.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/sp-capital-iq-initiates-coverage-on-angle-plc-in-sp-capital-iq-factual-stock-reports-300051003.html
SOURCE S&P Capital IQ
